Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...

Detailed price information for Mindbio Therapeutics Corp. (MBIO-CN) from The Globe and Mail including charting and trades.

What’s on CS111: The final covers programming basics, data structures, algorithms, recursion, and problem-solving, often through multiple-choice and coding questions. How to prepare: Review lectures ...

From designing algorithms to analyzing their efficiency, understanding these core concepts is key to solving problems in ...

ByteDance's drug unit showed an AI-designed IL-17 inhibitor at a Boston conference. The molecule targets interactions pharma called undruggable. Only trials will tell.

We’re being sold a world where there’s no room for reflection or spontaneity. This is the Black Mirror stage of capitalism, says Alexander Hurst, who writes for Guardian Europe from Paris ...

Najat Khan, CEO, opened by stating that Recursion is at an important inflection point, harnessing its integrated AI-driven platform to "translate insights into evidence; evidence that this platform, ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...